Chiromics

Chiromics and GlaxoSmithKline Enter into Collaboration

PRINCETON, N.J. – Chiromics LLC today announced a collaboration with GlaxoSmithKline (GSK) to discover novel classes of small molecules against certain biological targets.

Chiromics' compound collections are assembled using Chiromics' core chemical technology referred to as "cascade catalysis." This technology was invented in the MacMillan Laboratories at Princeton University. Cascade catalysis allows for the creation of "accessible complexity" – a diverse collection of molecules that is more complex than and differentiated from currently existing small molecule collections, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.

The combination of Chiromics' chemical compound collection of accessible complexity, and Chalis™, Chiromics' exclusive hit recognition algorithm for Affinity Screening, provides an opportunity for identification of new molecules, that is complementary to conventional high throughput screening processes.

Chiromics' founder David MacMillan, Ph.D., James S. McDonnell Distinguished University Professor of Chemistry and Chairman of the Chemistry Department at Princeton University, stated, "We are pleased to enter into this collaboration with GSK. This collaboration further validates that our chemical technology and discovery platform is a potentially valuable gateway to a new set of small molecules for drug discovery."

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

About Chiromics LLC

Chiromics LLC is a drug discovery company that designs and synthesizes broadly diverse chemical compound libraries, using a patented "cascade catalysis" technology that produces drug-like molecules with a stereochemically defined framework. The novel structures and accessible complexity of these compounds expands the access to important disease targets and accelerates the hit-to-lead time for identification of novel drugs.

Formed in 2009 and based in Princeton, N.J., Chiromics has established collaborations with leading biotech and pharmaceutical companies for licensing and screening of its libraries against a broad array of disease targets. For more information, visit www.chiromics.com.

# # #

Contact
Chiromics LLC
Colleen Plummer
267-968-0827
colleen@chiromics.com